Medium impactLayoffs

Sionna Therapeutics Cuts 46% of Staff in CF Pipeline Restructuring

NewsData.io · United States · Nov 10, 2026

Sionna Therapeutics (NASDAQ: SION) eliminated approximately 46% of its workforce in September as part of a strategic pivot to focus exclusively on a single cystic fibrosis drug pair, SION-451 and galicaftor. The company disclosed the cuts in its third-quarter earnings report on November 10, also announcing it would halt development of SION-719. The layoffs signal a significant reduction in headcount at this biotech firm, potentially freeing up specialized life-sciences talent in the candidate market.

Get the weekly brief by email

What changed in staffing last week, every Monday morning. Free. Unsubscribe anytime.

Sionna Therapeuticsbiotechnologylife sciencespharmaceuticals

Related stories